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Abstract
Background: Overpopulation, poor hygiene and disease prevention conditions in prisons are major structural
determinants of increased infectious risk within prison settings but evidence-based national and WHO guidelines
provide clear indications on how to reduce this risk. We sought to estimate the level of infectious risk by
measuring how French prisons adhere to national and WHO guidelines.
Methods: A nationwide survey targeting the heads of medical (all French prisons) and psychiatric (26 French
prisons) units was conducted using a postal questionnaire and a phone interview mainly focusing on access to
prevention interventions, i.e. bleach, opioid substitution treatment (OST), HBV vaccination and post-exposure
prophylaxis (PEP) for French prisoners. Two scores were built reflecting adherence to national and WHO
international guidelines, ranging from 0 (no adherence) to 10 (maximum adherence) and 0 to 9 respectively.
Results: A majority (N = 113 (66%)) of the 171 prisons answered the questionnaires, representing 74% coverage
(46,786 prisoners) of the French prison population: 108 were medical units and 12 were psychiatric units. Inmate
access to prevention was poor. The median[IQR] score measuring adherence to national guidelines was quite low
(4.5[2.5; 5.5]) but adherence to WHO guidelines was even lower 2.5[1.5; 3.5]; PEP was absent despite reported risky
practices. Unsuitable OST delivery practices were frequently observed.
Conclusions: A wide gap exists between HIV prevention policies and their application in prisons. Similar
assessments in other countries may be needed to guide a global policy reform in prison settings. Adequate
funding together with innovative interventions able to remove structural and ideological barriers to HIV prevention
are now needed to motivate those in charge of prison health, to improve their working environment and to
relieve French prisoners from their currently debilitating conditions.
Background
HIV prevention and risk reduction interventions in
prison settings are a major public health concern and a
critical political issue [1]. Infectious diseases are more
p r e v a l e n ti np r i s o nt h a ni nt h eg e n e r a lp o p u l a t i o na n d
many reports indicate that prison stay is an independent
risk factor for the transmission of blood-borne viruses’
[2-4]. Risky behaviors are frequent while the dramatic
prevalence of psychiatric disorders and the prison
context (lack of hygiene, promiscuity, sexual violence,
overpopulation and violence) exacerbate the risks [4-7].
Many inmates cycle in and out of prison repeatedly,
increasing the likelihood that any [4] infections con-
tracted in prison could soon affect the general commu-
nity [2,8].
In France, the prison population has increased by one
third in the last 10 years, partly due to the criminaliza-
tion of drug use. In 2008, 14.3% of sentences were for
drug-related offences, 36% of which involved prison sen-
tences [9].
The Ministry of Health has been responsible for
health in French prisons since 1994. National guidelines
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any medium, provided the original work is properly cited.[10] recommend equity in access to prevention mea-
sures and continuity of care between the community
and prisons and back to the community. However, the
question of access to prevention measures for HIV and
other infectious diseases is not referred to in any great
detail in these guidelines. Such access is referred to in a
1996 Ministry of Health/Ministry of Justice joint circular
[11] regulating HIV prevention in prison settings in
which several harm reduction (HR) measures available
in the general community (including needle syringe
exchange programs) are not permitted.
The main objective of this national survey is to esti-
mate the level of infectious risk by measuring to what
extent French prisons adhere to international guidelines
for HIV prevention in prison and to national policies, as
regulated by the 1996 circular [11] and national guide-
lines [10]. A secondary objective is to identify which
particular characteristics of prison settings predict non-
adherence to national and WHO guidelines.
Methods
A nationwide survey targeting all French prisons was
conducted between November 2009 and May 2010. A
questionnaire focusing primarily on access to infectious
disease prevention and HR measures for French prison-
ers was first sent to the heads of medical (all prisons)
and psychiatric (26 prisons) units (see additional file 1:
ANRS-PRI
2 DE Inventory Questionnaire). Additional
detailed information about issues regarding access to
HIV prevention was gathered through a structured
phone interview. More specifically the questionnaire col-
lected data about characteristics of the prisons with 10
sections, accounting for a total of 46 items, each explor-
ing access to a specific prevention measure.
We defined “international guidelines for HIV preven-
tion in prison” as those recommendations provided by
WHO, in collaboration with UNAIDS and UNODC in
their document entitled “Effectiveness of interventions
to address HIV in prisons” which includes interventions
for preventing not only HIV but other infectious dis-
eases in prison settings [4]. This WHO document was
chosen from among several other tools and reports as it
is the most comprehensive document on HIV preven-
tion in prison settings.
Two scores of adherence to national and international
guidelines were built in order to both evaluate the
implementation of HIV prevention and other HR mea-
sures in French prisons and to estimate the level of
infectious risk. Table 1 reports items corresponding to
national and international guidelines and how adherence
to each specific recommendation was scored. Finally,
two global scores were built, for national and interna-
tional guidelines respectively, by summing the subscores
corresponding to each recommendation. Each subscore
was dichotomous (0 = non- adherence, 1 = adherence)
with the exception of the scores for opioid substitution
treatment and access to condoms. The corresponding
scores for these latter items varied between 0 and 2 in
order to give them a higher weighting, as their effective-
ness in HIV prevention has already been established [4].
Potential score ranges for measuring adherence were
as follows: 0 to 10 for national guidelines and 0 to 9 for
international guidelines. For each subscore, we com-
puted the proportion of prisons adherent to national
and WHO guidelines as well as their 95% confidence
intervals.
A linear regression model was used to assess the rela-
tionship between each prison characteristic and the level
of adherence to national and WHO guidelines.
The National Agency for Research on Aids and Viral
Hepatitis (ANRS) committee granted approval for the
project. As only aggregated and openly available data
were used in the study, authorization from the Commis-
sion Nationale Informatique et Liberté was not required.
Study group
A majority (N = 113 (66%)) of the 171 prisons answered
the questionnaires, representing 74% (46 786 prisoners)
of the French prison population: 108 (63%) medical
units and 12 (46%) psychiatric units. Finally, 103 prisons
having complete data for all the items used for assessing
adherence to national and WHO guidelines were
included.
Results
No significant difference was found between the struc-
tural characteristics of prisons included in the study and
those excluded.
Among the 103 selected prisons, covering 43 365
incarcerated subjects (69%), 62% are remand centers
(RC), 13% are both RC and prisons for persons sen-
tenced (PPS), and 25% are PPS only (including 5 secur-
ity prisons). Seventy four (72%) are male only prisons, 1
is a female only prison, and 28 are mixed male and
female prisons. Among the 103 prisons, 24% receive
juvenile offenders. The mean number of prisoners per
prison is 421, ranging from 36 to 3785.
Descriptive results
Table 2 shows, for each subscore, the proportion of
prisons adherent to national and/or WHO guidelines.
Bleach
Information about how to use bleach for HR purposes is
considered as accessible and intelligible for prisoners in
only 22% of prisons. Bleach distribution is absent in 10%
of prisons.
Prisons adherent to national or WHO bleach guide-
lines account for 14% and 6% respectively (Table 2).
Michel et al. BMC Public Health 2011, 11:400
http://www.biomedcentral.com/1471-2458/11/400
Page 2 of 8Condoms
Male condoms are available in nearly all prisons (95%).
Female condoms are available in only 21% of prisons.
Lubricants are distributed with condoms in only 51%
of prisons. When available (n = 99), condoms are most
often available only in medical units (96 prisons). In
20% of prisons they are also available in a different
location (most often external associations’ rooms,
libraries or visiting rooms). According to medical staff,
prisoners have knowledge of the availability of con-
doms and how to access this availability in 73% of
prisons.
National and WHO guidelines for condom access are
adhered to in 9% and 12% of prisons respectively (Table 2).
Opioid Substitution Therapy (OST)
In the 103 prisons, 3854 prisoners (9%) receive OST,
2607 buprenorphine (6%) and 1247 methadone (3%).
OST coverage among inmates ranges from 0% to 40%.
Medical staffs declare that they do not, or do not sys-
tematically renew the prescription of OST for prisoners
at entry in 11% of prisons, while in 13% OST is never
initiated at entry nor during incarceration; 23% never
initiate buprenorphine at entry nor during detention;
23% never initiate methadone. In 17% of all prisons
Table 1 Scoring method for computing adherence to national and WHO guidelines in French prisons (ANRS PRI
2DE)
French Guidelines* Score WHO Guidelines** Score
Information-
Education-
Communication
￿ Distribution of information, Flyers or other tools
on HIV, Hepatitis and IST prevention at prison
entry
￿ ANDHarm reduction, HIV, sexuality and hepatitis
education programs in prison settings
1 ￿ Availability of Information/education at entry or during
prison stay
￿ Peer education programs available
￿ ANDavailability of clean injecting equipment + condoms
(0 if not)
0.5
0.5
1
Testing -
Counseling
￿ Systematic HIV, HBV and HV testing proposed at
prison entry (RC) and during prison stay (all
prisons)
￿ ANDsystematic negative test return
1 ￿ Testing for HIV, HBV, HCV systematically proposed at entry
(RC) and during prison stay (all prisons)
￿ ANDavailability of clean injecting equipment + condoms
(0 if not)
1
Condoms -
Lubricants
￿ Available information on condoms and
lubricant access
￿ Male condoms and lubricants accessible and
female condoms accessible for prisons with
female prisoners,
￿ Condoms accessible in a place other than the
medical unit
2 if 3
items
1 if
only 2
items
0 if 1
or 0
item
￿ Condoms available in various locations
￿ Water-based lubricants available
￿ Male condoms and lubricants accessible and female
condoms accessible for prisons with female prisoners
1
0.5
0.5
2
Opioid
Substitution
Therapy
￿ Induction at entry (RC) + induction during
prison stay + continuity of OST at entry (all
prisons)
1 ￿ Induction at entry (RC) + induction during prison stay +
continuity of OST at entry (all prisons)
1
￿ No ceiling dosage 0.5 ￿ No ceiling dosage 0.5
￿ No BHD crushing or dilution
0.5
2
￿ No BHD crushing or dilution 0.5
2
Bleach ￿ Existing and intelligible information on the use
of bleach in harm reduction for all prisoners
￿ ANDBleach renewal at least every 2 weeks
1 ￿ At least 2 locations/access for bleach inside prison
(penitentiary distribution, purchasable inside prison,
available in medical unit)
￿ ANDIntelligible information for HR purpose accessible for
all prisoners
1
HBV Vaccination ￿ Systematic HBV vaccination proposal for all
seronegative prisoners
1 Not applicable
Post-Exposition
Prophylaxis
￿ All prisoners informed of the PEP availability
inside prison
1 ￿ All prisoners informed of the PEP availability inside prison 1
Hair cutting
procedures/
protocols
￿ Existing hair cutting disposal or protocol 1 Not applicable
Needle Exchange
Programs
Not applicable ￿ NEP are available 1
TOTAL 10 9
* References are the1996 French Ministry of Health/Ministry of Justice joint circular and the 2004 Ministry of Health/Justice National Guidelines
**Reference is the 2007 WHO report untitled “Effectiveness of interventions to address HIV in prisons. Evidence for action technical papers. Geneva, WHO-
UNODC-UNAIDS”
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methadone, despite the lack of any officially established
threshold. Nearly one fifth of prisons crush or dilute
buprenorphine, three prisons applying both practices.
Only 27% of prisons are completely adherent to both
national and WHO guidelines in terms of access to
OST (Table 2).
BBV screening
Concerning BBV screening, 91%, 90% and 89% of the
heads of medical staff declare to systematically propose
screening at entry for all prisoners for HIV, HBV and
HCV respectively. Negative test results are systematically
provided to prisoners in 70%, 64% and 65% of cases for
HIV, HBV and HCV respectively. In 102 prisons, testing
for HIV, HBV or HCV is possible during detention.
Seventy four percent of prisons are adherent to
national guidelines while no prison is adherent to WHO
guidelines (Table 2). This is because international guide-
lines state that BBV screening should always be accom-
panied by access to clean injecting equipment and
condoms (Table 1).
HBV Vaccination
When prisoners are HBV negative, 83% medical units
systematically propose vaccination to inmates, so they
adhere to national guidelines on prevention (Table 2).
HBV vaccination in prison settings is not mentioned in
the WHO guidelines used as reference. It is however
recommended, especially for injecting drug users, in dif-
ferent WHO reports including “Health in prisons - a
WHO guide to the essentials in prison health”, 2007.
Information, Education, Communication on BBV, STI and
harm reduction
According to the heads of medical units, the distribution
of flyers or other tools on HIV hepatitis and IST pre-
vention is performed at prison entry in 86% of prisons
but also during detention in 90% of prisons. HR, HIV,
sexuality and hepatitis education programs provided by
peers or external clinical staff (NGOs, associations or
care units) are available in 77% of prisons.
Sixty eight and no (0%) prisons adhere to national and
WHO guidelines on information and education for pre-
vention concerns respectively (Table 2).
PEP or care for consequences of risk practices
Medical staffs declare that prisoners have no knowledge
of PEP availability in 47% of prisons and report being
unable to answer PEP related questions in 31% of pris-
ons. During the 12 months preceding this study, only 3
PEP were prescribed for prisoners (none for drug use).
Thirty five (34%) heads of medical units declare provid-
ing care to prisoners for abscesses possibly due to injec-
tion practices.
Twenty-three percent of prisons are adherent to both
national and WHO guidelines (Table 2).
Haircutting
French guidelines also provide recommendations for
prevention of blood-borne viruses (BBV) transmitted
through unsafe hair-cutting procedures based on the
availability of sterile material and a standardized proto-
col. This issue is not dealt with in WHO guidelines.
Thirty four (33%) prisons are adherent to national
hair-cutting guidelines (Table 2).
Needle syringe programs (NSP)
WHO guidelines underline the need to implement NSP
as a major tool for HIV prevention in prison settings.
However, they are not mentioned in French guidelines.
Because of this, adherence to national guidelines cannot
be computed and consequently no prison is adherent to
WHO guidelines.
Adherence to national and WHO guidelines
Figures 1A and 1B show the level of adherence to
national and WHO guidelines respectively.
The adherence score for national guidelines ranged
between 1 to 10, median values remaining rather low (4.5
[2.5; 5.5]) as Figure 1A shows. The distance between each
bar and the expected adherence value highlighted a large
area over the curve, providing a visual estimate of the dis-
tance between national guidelines and local practices.
As reported in Figure 1B the adherence score for
WHO guidelines ranged between 0 to 9 and median
values remained low (2.5[1.5; 3.5]), which confirms the
gap between international guidelines and practices.
Relationship between prison characteristics and the level
of adherence to guidelines
Apart from PPS, which presented lower national adher-
ence scores than RC, no other relationship was found
between characteristics of prisons (Table 3) and the
level of adherence to national or WHO guidelines.
Table 2 Proportion of prisons adherent to national and
WHO guidelines for each sub-score composing the global
adherence score (ANRS PRI
2DE) (N = 103 prisons)
France
% [95%CI]
WHO
% [95%CI]
Bleach: access and information 14 [7-20] 6 [1-10]
Condom & Lubricants: access and information 9 [3-14] 12 [5-18]
Opioid Substitution Treatment 27 [18-36] 27 [18-36]
HIV-HCV-HBV Screening 64 [55-74] 0%*
HBV vaccination 83 [75-90] NA
Information Education Communication 66 [57-75] 0%*
Post-Exposition Prophylaxis 23 [14-31] 23 [14-31]
Hair cutting measures 33 [24-42] NA
NSP NA 0%**
* A condition of simultaneous availability of condoms and NSP (not
authorized in French prisons) is required in WHO guidelines
** NSP are not authorized in French prisons but are available in the
community. NA = Not Available
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This study, the first conducted in France on access to
HIV prevention interventions and availability of HR
tools in prison settings clearly shows a wide gap
between national & international policies and local
practices. Adherence to national guidelines on availabil-
ity of information and access to HIV prevention and HR
measures is very poor, and preventive measures like
NSP promoted by WHO guidelines are absent, even as
local initiatives.
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Figure 1 Gap (in green) between national guidelines (A), WHO guidelines (B) and practices in French prisons (N = 103) as expressed
by the level of adherence score (0 = no adherence, 10 = max adherence and 0 = no adherence, 9 = max adherence, respectively).
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that practices depend on the ideology of the local
administration even if they are not evidence-based.
When focusing on each specific tool for HIV preven-
tion or HR, the heterogeneity of practices and gaps
between national and international policies becomes
more striking: such is the case for bleach distribution,
NSP, PEP and HBV vaccination.
Bleach effectiveness as a disinfectant for inactivating
HIV and particularly HCV is limited in prison settings
[4]. Bleach distribution does not meet the regulations
expressed by the French 1996 circular in two thirds of
prisons and the information about its use as a HR tool
is often absent. This may be due to the shared responsi-
bility with the criminal justice administration regarding
the distribution of information, to insufficient training
in health care units but also to a lack of a comprehen-
sive and clear HR policy in French prisons [12].
Condoms are almost always available in French prison
settings but in nearly half of the cases without lubricants
and in three quarters of the prisons, access is restricted
to medical units where confidentiality is limited. Sexual-
ity in prison is still a taboo because it refers to homo-
sexuality, which is an especially stigmatized practice in
prison. Although prison OST coverage is progressively
scaling-up (2% of the prison population in 1998 - 2
years after the Marketing Authorization Application in
France - reaching 8.9% in 2010), this is more probably a
reflection of increased coverage in the French opioid
dependent population. OST initiation remains proble-
matic and the use of a ceiling dosage prescription which
is not consistent with official guidelines is often
observed. Buprenorphine crushing or diluting practices
to reduce the risk of diversion, underscore the difficul-
ties met by health staff when trying to balance the risk
of diversion with adequate care for opioid dependence,
and suggest that fear of buprenorphine diversion in pris-
ons may represent a major barrier to its access.
BBV testing at prison entry is widely proposed but
according to a previous survey of prison settings, only a
small percentage of prisoners agree to be tested [12].
The proportion of inmates vaccinated against HBV on
prison entry increased from 13.7% in 1997 to 31.3% in
2003, probably thanks to the HBV vaccination campaign
in the general population [12]. As a history of incarcera-
tion has consistently been found to be a major predictor
of HBV seropositive status [13,14], accelerated strategies
based on injection at days 0, 10 and 21 which are easy
to perform and remain effective, need to be urgently
introduced in prison settings.
The currently poor access to and implementation of
PEP interventions in prisons is unfortunate and this is
one of the fields, together with HBV vaccination, which
deserves major attention. Information for prisoners
about the existence of such HRt o o l si sr a r e l ya v a i l a b l e
and no such treatment is prescribed for risky injection
practices.
At the international level, only a few studies on the
accessibility of HIV prevention and HR measures in
prison settings are available. In terms of bleach, NSPs
and condoms, most associated studies are from Austra-
lia and Canada, where confidentiality or anonymity are
Table 3 Relationship between structural prison factors and adherence to national and WHO guidelines using
univariate linear regression (N = 103)
National guidelines WHO guidelines
N (%) Coefficient (95%) p-value Coefficient (95%) p-value
Type of prison:
- RC* (ref) 77 (75)
- PPS** 21 (20) -1.10 (-1.89; -0.30) 0.01 0.03 (-0.51; 0.56) 0.92
- Security PPS 5 (5) -0.64 (-2.13; 0.85) 0.40 -0.05 (-1.05; 0.96) 0.93
Number of prisoners:
- < 100 (ref) 17 (17)
- 100-350 40 (39) -0.12 (-1.09; 0.86) 0.81 -0.25 (-0.87; 0.37) 0.43
- 350-600 23 (22) -0.07 (-1.15; 1.00) 0.89 0.11 (-0.58; 0.80) 0.76
- > = 600 23 (22) 0.08 (-1.00; 1.16) 0.88 0.15 (-0.54; 0.84) 0.67
Psychiatric Unit:
- no (ref) 85 (83)
- yes 18 (17) 0.69 (-0.17; 1.55) 0.11 0.14 (-0.42; 0.70) 0.61
Main practitioner gender: (n = 97)
- male (ref) 79 (81)
- female 18 (19) -0.06 (-0.92; 0.80) 0.89 -0.28 (-0.84; 0.29) 0.33
* RC: Remand Center
** PPS: Prison for Persons Sentenced
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in more than 50 prisons in 12 countries worldwide,
mostly in Europe [3]. In Germany, one evaluation
reported only a small reduction in syringe sharing in
one program, due to insufficient supply of needles and
syringes, access without anonymity and inadequate pro-
vision of correct sized syringes [4]. Condoms, in theory,
are widely accessible in many countries, except in the
United States where they are available in less than 1% of
prisons [4]. In reality, condoms are often not accessible
for different reasons [19], lack of anonymity being a fre-
quently cited example [4].
One major advantage of our survey is its capacity to
investigate not only accessibility to tools for reducing
the risk of infection in prison but also the general infor-
mation transmitted to inmates about the availability of
HR tools. It is important to underline that wide scale
care assessment in prison settings is rare, because it is
particularly difficult to carry out. Official authorization,
funding and agreement from ethics committees are only
rarely obtained [20]. A second advantage is that the
study can be easily replicated in other countries for
international comparisons and guide a global policy
reform to improve HIV prevention and general care in
prison settings.
Some limitations need to be acknowledged. Although
self-reports and interviews serve as the only feasible
methods to study access to prevention, they may be
affected by social desirability bias. However, while the
risk of over-reporting availability of preventive mea-
sures was high in our study, adherence rates were
rather low, suggesting that true rates are likely to be
even lower. Although no significant difference was
found between the structural characteristics of prisons
included in the study and those excluded, it is possible
that the former could be more concerned by preven-
tion/harm reduction issues. Accordingly, we can pre-
sume that we selected those more likely to be adherent
to national or international guidelines. This means that
the level of adherence to national and WHO guidelines
is likely to have been overestimated, which in turn
strengthens our conclusions.
Secondly, it is also possible that physicians may not
have been sufficiently informed about the interventions
p r o m o t e db yt h ep r i s o na d m i n i s t r a t i o ni nw h i c ht h e y
worked, but this could only be the case for bleach distri-
bution, whose access depends on the penitentiary
administration. Although the provision of care to reduce
harms from injecting practices is frequently reported,
drug injection remains a taboo practice in prison set-
tings because drug use is criminalized both in prison
and in the general community. This criminalization con-
tributes to making the introduction of NSPs useless and
hindering the full implementation of initiatives for
reducing harm in the injecting drug inmate population.
Despite these issues, in a French survey conducted
among drug users in the community, 12% reported
injecting practices in prison settings [21].
The failure in the implementation of a global HR
strategy in prison settings can be attributed to many
causes, but the primary one is that criminal justice laws
and drug prohibition still prevail over the public health
objectives of equity of access to prevention and care,
both in prison and in the general community.
In the last ten years, the reinforcement of the crimina-
lization of drug use has had a twofold effect. First it
constitutes a barrier to the implementation of an effec-
tive HR policy in the community, decriminalization
being associated with a reduced HIV prevalence among
drug users [22].
Secondly, the criminalization of drug use has contrib-
uted to overpopulation in prisons. This has not been
counterbalanced by the adequate implementation of pre-
ventive measures to control the increased risk of infec-
tion due to promiscuity or by an increase in health care
funds which could improve the coordination and deliv-
ery of existing HR interventions. More globally with
regard to health and hygiene, prison conditions for
French inmates are so deplorable that interventions to
reduce harm from drug use are probably not considered
as a priority for health care providers and administrative
professionals working in prison settings.
On the other hand, national and international guide-
lines are mainly designed for HIV prevention and are
rapidly becoming obsolete in terms of the emerging risk
of other infectious diseases like tuberculosis, hepatitis or
sexually transmissible diseases. The control of HCV in
correctional settings needs implementation of additional
preventive measures and/or of a HR package. In terms
of health policy, it would be more valuable if national
and international guidelines could anticipate policies to
control emerging public health problems in correctional
settings.
Conclusions
A policy reform for HIV prevention and HR in prison
settings is a priority but needs to be incorporated into a
wider national health policy reform to improve the gen-
eral health and quality of life of French prisoners as well
as equalizing access to care and prevention in prisons
and the general community. A drug policy reform decri-
minalizing drug use seems to be the sine-qua-non con-
dition for replacing incarcerations for the use of drugs
with improved access to prevention and care for drug
dependence.
HR will not be more effective in prison settings unless
innovative interventions and adequate funding are intro-
duced to motivate prison health and administrative staff,
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Page 7 of 8improve their working environment and finally relieve
the debilitating somatic and psychological conditions of
French prisoners.
Additional material
Additional file 1: ANRS-PRI
2 DE Inventory Questionnaire. This file
presents the questionnaire, collecting data about characteristics of the
prisons with 10 sections, accounting for a total of 46 items, each
exploring access to a specific prevention measure.
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